Randomized Phase 3 Trial of the Hypoxia Modifier Nimorazole Added to Radiation Therapy With Benefit Assessed in Hypoxic Head and Neck Cancers Determined Using a Gene Signature (NIMRAD).
Thomson DJ, Slevin NJ, Baines H, Betts G, Bolton S, Evans M, Garcez K, Irlam J, Lee L, Melillo N, Mistry H, More E, Nutting C, Price JM, Schipani S, Sen M, Yang H, West CM; NIMRAD Trial Group.
Thomson DJ, et al. Among authors: price jm.
Int J Radiat Oncol Biol Phys. 2023 Dec 9:S0360-3016(23)08184-1. doi: 10.1016/j.ijrobp.2023.11.055. Online ahead of print.
Int J Radiat Oncol Biol Phys. 2023.
PMID: 38072326
Free article.